Literature DB >> 26507073

Current and Emerging Medical Therapies for Gastroparesis.

Xiaofeng Zhao1, Hiroshi Mashimo2.   

Abstract

OPINION STATEMENT: Gastroparesis likely involves various pathophysiological disorders and is increasingly prevalent as complications of surgeries, medications, and chronic diabetes. Key to diagnosis is evidence of delayed gastric emptying, generally based on standardized scintigraphy, and ruling out distal obstruction or other dysmotilities. Initial medical management includes reviewing potentially exacerbating medications and ruling out other reversible causes, achieving tighter glucose control in diabetics, and implementing dietary and lifestyle changes. While current available medications are limited, symptomatic control is aimed at improving gastric emptying, alleviating nausea and vomiting, and treating associated abdominal pain. Other potential therapies are aimed at reducing acid production, improving gastric accommodation or pyloric dysfunction, and treating bacterial overgrowth. Future studies should be aimed toward identification of subpopulations of gastroparetics who are better responders to the various medications based on differences in underlying pathophysiology and adopting standardized study end point measures that may allow for comparisons across trials. This chapter will review current treatment options, upcoming promising medications, and some of the hurdles in advancing the field forward.

Entities:  

Keywords:  Gastroparesis; Medical treatment

Year:  2015        PMID: 26507073     DOI: 10.1007/s11938-015-0071-x

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  92 in total

1.  Gastric electrical stimulation improves outcomes of patients with gastroparesis for up to 10 years.

Authors:  Richard W McCallum; Zhiyue Lin; Jameson Forster; Katherine Roeser; Qingjiang Hou; Irene Sarosiek
Journal:  Clin Gastroenterol Hepatol       Date:  2010-12-23       Impact factor: 11.382

2.  Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia.

Authors:  J Tack; P Janssen; R Bisschops; R Vos; T Phillips; G Tougas
Journal:  Neurogastroenterol Motil       Date:  2010-10-27       Impact factor: 3.598

Review 3.  Prokinetics in gastroparesis.

Authors:  Andres Acosta; Michael Camilleri
Journal:  Gastroenterol Clin North Am       Date:  2014-12-23       Impact factor: 3.806

4.  Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis.

Authors:  Kellie Simmons; Henry P Parkman
Journal:  Dig Dis Sci       Date:  2014-03-11       Impact factor: 3.199

5.  A ghrelin agonist fails to show benefit in patients with diabetic gastroparesis: let's not throw the baby out with the bath water.

Authors:  M Camilleri; A Acosta
Journal:  Neurogastroenterol Motil       Date:  2013-09-03       Impact factor: 3.598

6.  Effects of fedotozine on gastric emptying and upper gastrointestinal symptoms in diabetic gastroparesis.

Authors:  K L Jones; J M Wishart; M K Berry; J L Abitbol; M Horowitz
Journal:  Aliment Pharmacol Ther       Date:  2000-07       Impact factor: 8.171

7.  Benefits of acupuncture for diabetic gastroparesis: a comparative preliminary study.

Authors:  Netanella Danielli Miller; Elad Schiff; Eran Ben-Arye; Joelle Singer; Tsachi Tsadok Perets; Shlomit Flaut; Nadav Sahar; Yaron Niv; Ram Dickman
Journal:  Acupunct Med       Date:  2013-12-09       Impact factor: 2.267

8.  Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis.

Authors:  J Arts; L Holvoet; P Caenepeel; R Bisschops; D Sifrim; K Verbeke; J Janssens; J Tack
Journal:  Aliment Pharmacol Ther       Date:  2007-11-01       Impact factor: 8.171

9.  Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics.

Authors:  Andrea Shin; Michael Camilleri; Irene Busciglio; Duane Burton; Elizabeth Stoner; Patrick Noonan; Keith Gottesdiener; Steven A Smith; Adrian Vella; Alan R Zinsmeister
Journal:  Diabetes Care       Date:  2012-09-06       Impact factor: 19.112

10.  Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth.

Authors:  Victor Chedid; Sameer Dhalla; John O Clarke; Bani Chander Roland; Kerry B Dunbar; Joyce Koh; Edmundo Justino; Eric Tomakin; Gerard E Mullin
Journal:  Glob Adv Health Med       Date:  2014-05
View more
  1 in total

1.  From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis.

Authors:  Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2017-06-02       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.